Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Regulatory News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

7 Jan 2022 17:37

RNS Number : 8381X
Midatech Pharma PLC
07 January 2022
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BKT14T00

Issuer Name

MIDATECH PHARMA PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Cantor Fitzgerald Europe

City of registered office (if applicable)

 

Country of registered office (if applicable)

GB

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

06-Jan-2022

6. Date on which Issuer notified

07-Jan-2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

5.200968

0.000000

5.200968

5121309

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BKT14T00

5121309

5.200968

Sub Total 8.A

5121309

5.200968%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

 

13. Place Of Completion

UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLBRMRTMTJMBIT
Date   Source Headline
27th Feb 20194:40 pmRNSSecond Price Monitoring Extn
27th Feb 20194:35 pmRNSPrice Monitoring Extension
27th Feb 201910:52 amRNSHolding(s) in Company
26th Feb 201911:26 amRNSFinalisation of Licence Agreement
25th Feb 201912:23 pmRNSResult of the General Meeting and Board changes
8th Feb 20194:39 pmRNSPosting of Circular and Notice of General Meeting
4th Feb 20196:32 pmRNSResult of Placing
4th Feb 20193:16 pmRNSProposed Placing and Open Offer
29th Jan 20199:23 amRNSStrategic Investment & Licence Agreement
25th Jan 20197:00 amRNSFDA feedback on clinical plan for MTD201
15th Jan 20191:56 pmRNSHolding(s) in Company
15th Jan 20199:36 amRNSHolding(s) in Company
11th Jan 201910:58 amRNSHolding(s) in Company
10th Jan 201911:15 amRNSMidatech announces EUR 1.5 million loan facility
20th Dec 20187:00 amRNSCorporate update and potential fundraise
20th Dec 20187:00 amRNSMidatech Announces Microsphere Partnership
28th Nov 20181:17 pmRNSHolding(s) in Company
20th Nov 201812:59 pmRNSHolding(s) in Company
5th Nov 20189:55 amRNSHolding(s) in Company
1st Nov 20185:48 pmRNSNASDAQ Minimum Bid Price Extension
1st Nov 20187:00 amRNSCompletion of Midatech Pharma US Sale
15th Oct 201812:17 pmRNSResult of General Meeting
28th Sep 201810:04 amRNSPosting of Circular and Notice of General Meeting
27th Sep 20187:01 amRNSInterim Results
27th Sep 20187:00 amRNSProposed Sale of Midatech Pharma US Inc
6th Sep 20187:00 amRNSNotice of Interim Results
31st Aug 20187:00 amRNSInterim results from MTD201 exploratory study
1st Aug 20187:00 amRNSIssue of Equity for Midatech Share Incentive Plan
25th Jul 20187:00 amRNSTrading Update
23rd Jul 20187:00 amRNSUS Co-Promotion Agreement
27th Jun 201810:56 amRNSResult of AGM
8th Jun 20187:00 amRNSMidatech US enrols patient in Gelclair trial
1st Jun 20187:00 amRNSBoard change
1st Jun 20187:00 amRNS2017 Annual Report and AGM Notification
25th May 20187:00 amRNSMidatech commences US clinical study with MTX110
21st May 20187:00 amRNSMidatech commences dosing in equivalence study
8th May 20187:00 amRNSSEC filing regarding share price movement
3rd May 201812:15 pmRNSMidatech Announces Receipt of NASDAQ Notice
3rd May 20187:00 amRNSStmnt re Share Price Movement
2nd May 20184:40 pmRNSSecond Price Monitoring Extn
2nd May 20184:35 pmRNSPrice Monitoring Extension
23rd Apr 20187:00 amRNSFinancial results for year ended 31 December 2017
9th Apr 20188:25 amRNSNotice of Results
15th Mar 20187:00 amRNSChanges in Senior Management Team
28th Feb 20187:00 amRNSMidatech gets Orphan Drug Designation for MTD119
14th Feb 20187:00 amRNSTrading Update
16th Jan 20187:00 amRNSIND approval for DIPG treatment MTX110
9th Jan 20187:00 amRNSQ-Octreotide first in-human EU study approved
3rd Jan 20181:36 pmRNSHolding(s) in Company
2nd Jan 20187:00 amRNSMidatech Loan Agreement with MidCap Financial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.